Company Overview and News
The companies were purchased for their collective potential to deliver very solid total returns, but offering less volatility through a major market correction.
ABT LOW TXN WBA UTX CVS WMT MDT NKE JNJ CL MSFT QCOM MMM
DUBLIN - July 12, 2018 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) labeling expansion for the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead to include stimulation of the bundle of His. It is the only pacing lead on the market approved for His-bundle pacing (HBP).
DUBLIN - July 11, 2018 - Medtronic plc (NYSE: MDT) has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD(TM) System, a left ventricular assist device (LVAD) for patients with advanced heart failure. The HVAD System is the smallest commercially available LVAD, and the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest.
On Jul 6, we issued an updated research report on Medtronic plc (MDT - Free Report) . While we are encouraged by the company’s global accepted advanced therapies, its escalating costs and expenses raise concerns. The stock has a Zacks Rank #3 (Hold).
ALGN SYK GHDX MDT
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
I collected a personal record $865 of dividends in June and a total of $1933 in Q2.
WFCNP HD WFC.PRL WFC.PRJ PRU WFC.PRT WFC.PRR WFC.PRQ WFC.PRP SWK WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV MO WFC PRU WFC.WS DUKH GLW PFK DUK UTX CMI MDT PEP JNJ PRH SBUX PJH
Management recently set long-term financial targets, and investors are primarily focused on 4%+ organic revenue growth. Diabetes segment performance will be key to hitting this target.
Chicago, IL – June 29, 2018 – Zacks Equity Research highlights Polaris Industries (PII - Free Report) as the Bull of the Day and BlackRock Capital (BKCC - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onIntuitive Surgical, Inc. (ISRG - Free Report) , Medtronic plc (MDT - Free Report) and NuVasive, Inc. (NUVA - Free Report) .
WFC WFCNP WFC.WS WFC.PRL WFC.PRJ ISRG HOG MDT WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN NUVA WFC.PRY PII WFC.PRX WFC.PRW WFC.PRV
The United States has hit rough waters of late. Few analysts label the troubles as self-invited while others foresee a revolution. Rising trade war tensions between the United States and China are showing no signs of abatement. The issue has escalated to a point where imposition of tariffs and retaliatory tariffs may go up to $450 billion on both the sides.
NUVA ISRG MDT
DUBLIN- June 28, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the launch of the MiniMed(TM) 670G Performance Guarantee Program - an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this Guarantee, Medtronic will provide flat-fee reimbursements up to $25,000 per pump over 4 years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States.
11h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to MDT / Medtronic plc on message board site Silicon Investor.
as of ET